BLASUBCUTANEOUSINJECTABLE
Approved
Aug 2025
Lifecycle
Launch
Competitive Pressure
30/100
Data completeness
5/8 — Partial
LEQEMBI IQLIK (lecanemab-irmb) by Eisai is amyloid beta-directed antibody interactions [moa]. Approved for amyloid beta-directed antibody [epc]. First approved in 2025.
Drug data last refreshed 4d ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LEQEMBI IQLIK (lecanemab-irmb) is a monoclonal antibody directed against amyloid beta, approved for Alzheimer's disease in August 2025. It is administered subcutaneously and works by binding to amyloid beta to reduce accumulation in the brain. This represents a disease-modifying approach distinct from older symptomatic treatments.
Launch
Early-stage launch with moderate competitive pressure (30/100); team will focus on market penetration, payer access, and establishing clinical adoption against entrenched symptomatic therapies.
Mechanism of Action
Amyloid Beta-directed Antibody Interactions
Pharmacologic Class:
Amyloid Beta-directed Antibody
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Worked on LEQEMBI IQLIK at Eisai? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.